Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation

Non-alcoholic fatty liver (NAFLD) disease causes degeneration of the liver, affects about 25% of people globally, and has no approved treatment. Here, the authors show that the therapeutic siRNA-driven silencing of MCJ in the liver is an effective and safe treatment for NAFLD in multiple mouse model...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Lucía Barbier-Torres, Karen A. Fortner, Paula Iruzubieta, Teresa C. Delgado, Emily Giddings, Youdinghuan Chen, Devin Champagne, David Fernández-Ramos, Daniela Mestre, Beatriz Gomez-Santos, Marta Varela-Rey, Virginia Gutiérrez de Juan, Pablo Fernández-Tussy, Imanol Zubiete-Franco, Carmelo García-Monzón, Águeda González-Rodríguez, Dhaval Oza, Felipe Valença-Pereira, Qian Fang, Javier Crespo, Patricia Aspichueta, Frederic Tremblay, Brock C. Christensen, Juan Anguita, María Luz Martínez-Chantar, Mercedes Rincón
Format:	article
Langue:	EN
Publié:	Nature Portfolio 2020
Sujets:	Science Q
Accès en ligne:	https://doaj.org/article/f4585c15ec8641c2ad4a105f86c1a9ca
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

Silencing hepatic MCJ attenuates non-alcoholic fatty liver disease (NAFLD) by increasing mitochondrial fatty acid oxidation

Documents similaires